T-cell therapy method
AssigneesImmunotech Biopharm Co., Ltd., Pharos Vaccine Inc., National Institutes for Food and Drug Control
InventorsYu Wang, Hyunsoo Lee, Namchul Jung, Youchun Wang, Lei Sun, Qiang Liu, Yonghua Zhang, Meng Wang
Life of this patent
Estimating the term…
Abstract
The present invention belongs to the field of biomedicine. Specifically, the present invention relates to an improved T-cell therapy. More specifically, the present invention relates to enhancing the cancer treatment efficacy of therapeutic T cells (such as CAR-T or TCR-T cells) through stimulation with living cells expressing cancer-related antigens.
Claims17
A method for treating CD19-expressing cancer in a subject or for preventing CD19-expressing cancer progression or recurrence in a subject, comprising the following steps:
- (a) administering therapeutic T cells specifically targeting a cancer-related antigen to the subject;
- and
- (b) administering cells expressing the cancer-related antigen to the subject,
- wherein the cells expressing CD19 are non-irradiated living cells expressing CD19,
- wherein the therapeutic T cells are T cells (CAR-T cells) comprising a chimeric antigen receptor (CAR) specifically targeting CD19,
- wherein the cells expressing CD19 are administered after the administration of the therapeutic T cells.
Dependencies are inferred from the claim text.